262 filings
10-Q/A
2024 Q1
BIXT
Bioxytran, Inc
Quarterly report (amended)
22 Apr 24
3:39pm
10-Q
2024 Q1
BIXT
Bioxytran, Inc
Quarterly report
19 Apr 24
4:50pm
8-K
BIXT
Bioxytran, Inc
19 Apr 24
Material Modifications to Rights of Security Holders
4:26pm
10-K
2023 FY
BIXT
Bioxytran, Inc
Annual report
22 Mar 24
5:17pm
10-Q
2023 Q3
BIXT
Bioxytran, Inc
Quarterly report
2 Nov 23
7:35pm
424B4
giaktom
2 Oct 23
Prospectus supplement with pricing info
11:36am
EFFECT
1ay9h
2 Oct 23
Notice of effectiveness
12:15am
CORRESP
di39ihf
28 Sep 23
Correspondence with SEC
12:00am
UPLOAD
w4vpv7
26 Sep 23
Letter from SEC
12:00am
CORRESP
y3zs3nzc
20 Sep 23
Correspondence with SEC
12:00am
8-K
suu7ry 3e4w2eb5
24 Aug 23
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
9:15am
EFFECT
ivsdzklhcvuk rn
15 Aug 23
Notice of effectiveness
12:15am
424B4
svi1o0gq5dlernk
14 Aug 23
Prospectus supplement with pricing info
8:07pm
CORRESP
a5odm5knio6hg2tk8c
10 Aug 23
Correspondence with SEC
12:00am